Skip to main content

Table 1 Patients’ outcomes

From: Impact of dexamethasone on the incidence of ventilator-associated pneumonia in mechanically ventilated COVID-19 patients: a propensity-matched cohort study

Parameter

Total (n = 316)

DEXA+ (n = 158, 50%)

DEXA (n = 158, 50%)

p value

RR/ Incidence RR (95% CI)

VAP, No. (% of the included patients)

144 (46%)

89 (56%)

55 (35%)

0.0001

1.61 (1.26–2.09)

VAP Incidence (No. × 1000 ventilation-pt/days; 95% CI)

40.76 (40.55–40.97)

49.58 (49.26–49.91)

31.65 (31.38–31.91)

< 0 .0001

1.57 (1.55–1.58)

VAP Severity, No. (% of the included patients)

Infection

80 (56%)

43 (48%)

37 (67%)

0.0496

 

Sepsis

32 (22%)

25 (28%)

7 (13%)

Shock

32 (22%)

21 (24%)

11 (20%)

Outcome ICU, No. (% of the included patients)

Discharged

216 (68%)

104 (66%)

112 (71%)

0.3332

1.17 (0.85–1.63)

Death

100 (32%)

54 (34%)

46 (29%)

ICU LOS (days)

15 [− 9 to 27]

17 [10–31]

14 [8–23]

0.0225

 

Mechanical ventilation (days)

14 [9–27]

16 [10–30]

13 [7–22]

0.0143

 

Time from hospitalization to infection (days)

10 [6–16]

10 [6–16]

10 [6–15]

0.9803

 

Time from ICU to infection (days)

7 [5–12]

7 [5–12]

7 [5–12]

0.6407

 

Time from intubation to infection (days)

7 [5–12]

7 [5–12]

7 [5–12]

0.5070

 
  1. Data are presented as absolute frequency (% of the included patients) or as median and interquartile range. RR, Risk Ratio; ICU, Intensive Care Unit; MDR, Multi-Drug Resistant; VAP, Ventilator-Associated Pneumonia; LOS, Length of Stay. Statistically significant variables are highlighted in bold